The short version of placebo-controlled trial fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-26 and is reviewed periodically as new material appears.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
| Property | Value | Notes |
|---|---|---|
| Research code | PT-141 | Used in early literature before the generic name became common |
| Generic name | Bremelanotide | International nonproprietary name |
| Peptide class | Cyclic heptapeptide | Seven residues joined by a lactam bridge |
| Primary receptor | MC4R | Lower affinity reported at MC1R, MC3R and MC5R |
| Route studied clinically | Subcutaneous injection | Intranasal route was abandoned after pressor effects |
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS). It is approved in the United States and Canada, and the European Union to treat systemic lupus erythematosus and lupus nephritis. The most common side effects include bacterial infections, such as bronchitis (infection in the lungs) and infection of the urinary tract (structures that produce or carry urine), diarrhea and nausea (feeling sick).
Directly dissolving SO3 in water, called the "wet sulfuric acid process", is rarely practiced because the reaction is extremely exothermic, resulting in a hot aerosol of sulfuric acid that requires condensation and separation. In the first step, sulfur is burned to produce sulfur dioxide:
Cassinga must be revenged." It was from this communique that the name of the next major PLAN offensive was derived: Operation Revenge. After some deliberation, Huwala chose Katima Mulilo as his target and dispatched several PLAN reconnaissance teams to obtain data on firing positions and potential artillery observation posts. On 23 August 1978, PLAN bombarded Katima Mulilo with mortars and rocket fire, killing 10 SADF personnel. The next day, General Viljoen, General Geldenhuys and the Administrator-General of South West Africa flew out to Katima Mulilo to inspect the damage. All three narrowly escaped death when their SA.321 Super Frelon helicopter took ground fire from PLAN anti-aircraft positions at Sesheke. The SADF responded by bombarding Sesheke with its own artillery and making a sweep for PLAN insurgents up to a hundred kilometers north of the Cutline. On 6 March 1979, Prime Minister Botha ordered retaliatory strikes on selected targets in Angola and Zambia. The respective code names for the operations were Rekstok and Saffraan. Heliborne South African troops landed in the vicinity of four Angolan settlements: Heque, Mongua, Oncocua, Henhombe, and Muongo, which they canvassed for guerrillas. The SADF remained in Zambia for a significantly longer period, carrying out a series of uneventful combat patrols and ambushes for five weeks. While Operations Rekstok and Saffraan were unsuccessful in terms of tactical results, they did interrupt PLAN's attempts to rebuild its base camps near the border.
multiple cloning site (MCS) Also polylinker. A locus or sequence within a plasmid vector which contains multiple unique restriction sites recognized by various restriction endonucleases, which makes it possible for scientists to target the insertion of a DNA fragment (often a gene cassette) specifically to that locus and in the desired orientation, by digesting the insert and the vector with the same endonuclease(s) and then ligating them together via compatible restriction ends, a technique known as restriction cloning. Commercial plasmids designed for cloning commonly incorporate one or more multiple cloning sites.
==== Children's books and other short works ==== In addition to his mythopoeic compositions, Tolkien enjoyed inventing fantasy stories to entertain his children. He wrote annual Christmas letters from Father Christmas for them, building up a series of short stories (later compiled and published as The Father Christmas Letters). Other works included Mr. Bliss and Roverandom (for children), and Leaf by Niggle (part of Tree and Leaf), The Adventures of Tom Bombadil, Smith of Wootton Major and Farmer Giles of Ham. Roverandom and Smith of Wootton Major, like The Hobbit, borrowed ideas from his legendarium.
Sources: en.wikipedia.org
=== Myomesin 1 === Myomesin 1 is the most researched of the forms of myomesin due to its presence in all striated muscles and that it is the largest of the myomesin class. It is sometimes just simply called myomesin because of it widespread expression. Myomesin 1 is found in mainly on the M4/M4' lines of the M-band. It is encoded by the MYOM1 gene. There are two variants of myomesin 1, one located between the My6 and My7 domains, and the other at the end of the C-terminal after the My13 domain. The prior is known as the embryonic heart (EH)-sequence and the latter, which has only been found in birds, is called the H or S splice variant (H is for heart and S is for skeletal). EH-myomesin can be found during embryonic development of the human heart (later replaced by myomesin 2). As the muscle matures, EH-myomesin is downregulated in favor of myomesin 1 with no genetic variations.
For some professional career programs, students are required to take the Saber-Pro test, in their final year of undergraduate academic education. Public spending on education as a proportion of gross domestic product in 2015 was 4.49%. This represented 15.05% of total government expenditure. The primary and secondary gross enrolment ratios stood at 113.56% and 98.09% respectively. School-life expectancy was 14.42 years. A total of 94.58% of the population aged 15 and older were recorded as literate, including 98.66% of those aged 15–24.
11 May – The Independent Press Standards Organisation rejects a complaint by former MP Scott Benton that an article published by The Times in April 2023 was in breach of IPSO's editors code. 12 May – Foreign Secretary David Cameron tells the BBC's Sunday with Laura Kuenssberg that a ban on the sale of UK weapons to Israel would only strengthen Hamas. Former Chancellor Nadhim Zahawi tells BBC News he has paid nearly £5m to authorities to settle his tax affairs. 13 May – The House of Commons approves plans to exclude MPs from the parliamentary estate if they have been arrested on suspicion of a serious offence. Health secretary Victoria Atkins says that more maternity care scandals are likely following a birth trauma report on maternity care services. Labour MP Rosie Duffield calls for the party to suspend Natalie Elphicke while investigating lobbying allegations. Labour MP Chris Bryant reveals he has skin cancer. A judge at the Northern Ireland High Court rules that the UK government's Illegal Migration Act should not apply in Northern Ireland because of human rights laws and the Windsor Framework. The UK government scraps a planned amendment to the Criminal Justice Bill that would give police the power to move homeless people on because of "smells" following opposition from Conservative MPs. 14 May – MSPs unanimously approve the Housing Cladding Remediation Bill with 116 votes in favour of the legislation that seeks to address problems with cladding on buildings and avoid a similar incident to the Grenfell Tower fire in Scotland.
=== Toxicokinetics === Inhaling cadmium-laden dust quickly leads to respiratory tract and kidney problems which can be fatal (often from kidney failure). Ingestion of any significant amount of cadmium causes immediate poisoning and damage to the liver and the kidneys. Compounds containing cadmium are also carcinogenic.
Sources: en.wikipedia.org
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.
MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.
Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.
Trial results generally show a small to moderate average improvement in desire scores relative to placebo. The distribution of responses is wide, and some participants show little measurable change. Group averages should not be read as a prediction for any single person.